Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)
Scope of the Report
The report titled “Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)” provides an in-depth analysis of global knee osteoarthritis market with special focus on non conservative treatment for OA such as Viscosupplementation. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2016-20). Further, key drug manufacturers of the global knee osteoarthritis market like Johnson & Johnson, Zimmer Biomet Holdings and Stryker Roche are profiled in the report.
Johnson & Johnson-DePuy
Zimmer Biomet Holdings, Inc.
Osteoarthritis is the most prevalent joint disease mainly affecting middle-age to elderly population globally. It can occur in any joint such as knees, hips, hands and spine; knee being one of the most affected joints. Knee osteoarthritis is a progressive, degenerative disorder involving the degradation of the intra-articular cartilage, joint lining, ligaments, and the underlying bone of the knee. There are many factors that can increase the risk of osteoarthritis in a person such as age, being overweight, genetic condition, etc. Sometimes a combination of these factors leads to such condition.
Treatments for knee OA are based on the stage of disease. Depending on the severity of OA, there are different approaches and treatments available that helps the patient with lessening the pain and increasing mobility. Conservative approach is used for treatment in initial stages of OA. With increase in severity Cortisone injections and Viscosupplementation are used.
Global knee osteoarthritis market is driven by increase in geriatric population, high rate of obesity, rising healthcare expenditure and high incidence of knee OA in the US market. Factors which are affecting the industry includes decline in reimbursement and coverage, defective medical devices, lack of trained healthcare workers and regulatory risk. The market is characterized by growth in Outsourced Precision Manufacturing segment and advent of HA single injection from non-animal source.